Chemotherapy-related skin toxicities
Acneiform eruptions, or folliculitis, often begin as facial erythema that progress to papules and pustules and spread to the upper trunk. Causes of folliculitis in cancer patients include actinomycin-D (Cosmegen)—the most common—as well as epidermal growth factor receptor-inhibiting agents, such as gefitinib (Iressa) and cetuximab (Erbitux). Although the pustules contain no bacteria, oral tetracycline antibiotics can be used to manage eruptions due to the drugs’ anti-inflammatory properties.
Paronychia is an infection of the soft tissue around a finger or toenail leading to inflammation and swelling. It is a known toxicity of anti-cancer therapy with epidermal growth factor receptor-inhibiting (EGFR) agents. These drugs may affect the skin’s epidermal receptors and cause paronychia. Onset is typically within 2 months of initiating an EGFR agent, with reported incidence rates ranging between 6% and 50%.
Trichomegaly, the spontaneous, excessive growth of eyelash with a specifically curly texture, is a toxicity associated with epidermal growth factor receptor-inhibiting (EGFR) use, particularly erlotinib (Tarceva, generic), gefitinib (Iressa), and cetuximab (Erbitux). Researchers hypothesize that trichomegaly may help predict tumor response during EGFR blockade treatment. The biologic significance of trichomegaly remains unknown.
Patients undergoing chemotherapy with taxanes (docetaxel [Docefrez, Taxotere, generics] and paclitaxel [Abraxane, generics]) and anthracyclines (doxorubicin [Doxil, generics], idarubicin [Idamycin PFS, generics], and epirubicin [Ellence, generics]) are prone to nail changes including Beau line or transverse grooves in the nail plate (pictured), onycholysis, onychomadesis, and thickening/thinning of the nail. Nail pain may require pain medication. New growth typically resolves these conditions.
The chemotherapy drugs fluorouracil (Carac, Effudex, Fluoroplex, generics), vinorelbine (Navelbine, generics), and daunorubicin (Cerubidine, Daunoxome) cause hyperpigmentation of the skin, nails, and oral mucosa. Hyperpigmentation can follow the distribution of veins, known as serpentine supravenous hyperpigmentation, or can be patchy and macular. Topical hydroquinone can decrease melanin production and help clear hyperpigmentation. The disorder typically resolves when chemotherapy is stopped.
- PMPS: A Common Late Effect of Surgery and Radiation for Breast Cancer
- Breast Cancer Tumors Often a Composite of Tumor Types, Enhancing Treatment Resistance
- Physical Activity May Reduce Mortality by 44% in Patients With Breast Cancer
- Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed
- Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer
- Nurses Are Key to Referrals to Inpatient Integrative Medicine Services
- Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma
- Poor Compliance to Adjuvant Chemo Linked to Poorer Survival in Rectal Cancer
- Users Support Indoor Tanning Device Age Restrictions, Stronger Health Warnings, But Not Total Ban
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|